항염증 생물학적 제제 시장 규모 조사 및 예측 : 약제 클래스별, 용도별, 투여 경로별, 유통 채널별, 지역별 분석(2023-2030년)

Global Anti-Inflammatory Biologics Market is valued approximately at USD 93.13 billion in 2022 and is anticipated to grow with a growth rate of more than 5.9% over the forecast period 2023-2030. Anti-inflammatory biologics are advanced medications designed to target and reduce inflammation in the body, primarily used for treating conditions such as psoriasis, ulcerative colitis, rheumatoid arthritis and inflammatory bowel diseases has spurred demand for biologics. They work by interfering with specific molecules or pathways in the immune system, helping alleviate symptoms and prevent tissue damage. These biologics have transformed the treatment landscape for inflammatory conditions, offering relief to patients unresponsive to traditional therapies. The favorable reimbursement policies, rising aging population, increasing healthcare expenditure, and increased awareness of inflammation's are the most prominent factors that are propelling the market demand across the globe.

In addition, the surge in autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel diseases, and ulcerative colitis is a pivotal driver propelling market expansion. For instance, a study released by the NCBI in August 2021 reported a 3% prevalence of psoriasis among adults aged 20 years or older in the U.S., underlining the momentum in this arena. Likewise, according to the NCBI article published in September 2022, the incidence of rheumatoid arthritis in Northern Europe and Northern America was 24 and 36 cases per 100,000 people, respectively. Moreover, the swift adoption of biologics for treating inflammatory diseases and the favorable reimbursement landscape for biological therapies are poised to further bolster market advancement. Furthermore, the rise in investment in research activities for the development of biologics, as well as the growing advancements is biotechnology presents various lucrative opportunities over the forecasting years. However, the side effects of anti-inflammatory drugs and the lack of inclination for biologics as first line of treatment are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Anti-Inflammatory Biologics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 with largest market share owing to the surge in demand for anti-TNF drugs and promising pipeline candidates, serving as primary drivers propelling market growth. Furthermore, the strategic positioning of key players and robust sales of their pharmaceuticals in the region are anticipated to further bolster market expansion in North America. Whereas, Asia Pacific region is expected to grow the fastest over the forecast years. The increasing prevalence of diverse inflammatory disorders, rising healthcare spendings, and growing awareness regarding the available treatment options for these conditions are significantly propelling the market demand across the region.

Major market players included in this report are:

• AbbVie Inc. (U.S.)
• Merck & Co., Inc. (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• UCB S.A. (Belgium)
• Eli Lilly and Company (U.S.)
• Amgen Inc. (U.S.)
• Biogen (U.S.)

Recent Developments in the Market:

• In February 2023, Pfizer Inc. revealed that the U.S. Food and Drug Administration (FDA) granted approval to its supplemental New Drug Application (sNDA) for CIBINQO, intended for patients grappling with moderate-to-severe atopic dermatitis.
• In March 2022, AbbVie announced the approval of RINVOQ (upadacitinib) by the U.S. Food and Drug Administration (FDA) for treating adults diagnosed with ulcerative colitis.
• In September 2022, Bristol Myers Squibb reported the two-year outcomes from the POETYK PSO Long-Term Extension (LTE) trial, focusing on sustained Sotyktu treatment in adult patients diagnosed with plaque psoriasis.
• In October 2022, GSK plc offered insights into the ContRAst phase III program concerning otilimab, an investigational monoclonal antibody aimed at potentially treating moderate to severe rheumatoid arthritis.

Global Anti-Inflammatory Biologics Market Report Scope:

• Historical Data - 2020 - 2021
• Base Year for Estimation - 2022
• Forecast period - 2023-2030
• Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered - Drug Class, Route of Administration, Application, Distribution Channel, Region
• Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
• Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

• Anti-Tumor Necrosis Factor (TNF)
• Interleukins Antagonists
• Janus Kinase (JAK) Inhibitors
• Others

By Route of Administration:

• Oral
• Injection

By Application:

• Rheumatoid Arthritis
• Psoriasis
• Others

By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

• 1.1.Market Snapshot
• 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
  • 1.2.1.Anti-Inflammatory Biologics Market, by region, 2020-2030 (USD Billion)
  • 1.2.2.Anti-Inflammatory Biologics Market, by Drug Class, 2020-2030 (USD Billion)
  • 1.2.3.Anti-Inflammatory Biologics Market, by Route of Administration, 2020-2030 (USD Billion)
  • 1.2.4.Anti-Inflammatory Biologics Market, by Application, 2020-2030 (USD Billion)
  • 1.2.5.Anti-Inflammatory Biologics Market, by Distribution Channel, 2020-2030 (USD Billion)
• 1.3.Key Trends
• 1.4.Estimation Methodology
• 1.5.Research Assumption

Chapter 2.Global Anti-Inflammatory Biologics Market Definition and Scope

• 2.1.Objective of the Study
• 2.2.Market Definition & Scope
  • 2.2.1.Industry Evolution
  • 2.2.2.Scope of the Study
• 2.3.Years Considered for the Study
• 2.4.Currency Conversion Rates

Chapter 3.Global Anti-Inflammatory Biologics Market Dynamics

• 3.1.Anti-Inflammatory Biologics Market Impact Analysis (2020-2030)
  • 3.1.1.Market Drivers
    • 3.1.1.1.Surge in the number of autoimmune inflammatory conditions
    • 3.1.1.2.Favourable reimbursement policies
  • 3.1.2.Market Challenges
    • 3.1.2.1.Side effects of anti-inflammtory drugs
    • 3.1.2.2.Lack of inclination for biologics as first line of treatment
  • 3.1.3.Market Opportunities
    • 3.1.3.1.Rise in investment in research activities for development of biologics
    • 3.1.3.2.Growing advancements is biotechnology

Chapter 4.Global Anti-Inflammatory Biologics Market: Industry Analysis

• 4.1.Porter's 5 Force Model
  • 4.1.1.Bargaining Power of Suppliers
  • 4.1.2.Bargaining Power of Buyers
  • 4.1.3.Threat of New Entrants
  • 4.1.4.Threat of Substitutes
  • 4.1.5.Competitive Rivalry
• 4.2.Porter's 5 Force Impact Analysis
• 4.3.PEST Analysis
  • 4.3.1.Political
  • 4.3.2.Economical
  • 4.3.3.Social
  • 4.3.4.Technological
  • 4.3.5.Environmental
  • 4.3.6.Legal
• 4.4.Top investment opportunity
• 4.5.Top winning strategies
• 4.6.COVID-19 Impact Analysis
• 4.7.Disruptive Trends
• 4.8.Industry Expert Perspective
• 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Anti-Inflammatory Biologics Market, by Drug Class

• 5.1.Market Snapshot
• 5.2.Global Anti-Inflammatory Biologics Market by Drug Class, Performance - Potential Analysis
• 5.3.Global Anti-Inflammatory Biologics Market Estimates & Forecasts by Drug Class 2020-2030 (USD Billion)
• 5.4.Anti-Inflammatory Biologics Market, Sub Segment Analysis
  • 5.4.1.Anti-Tumor Necrosis Factor (TNF)
  • 5.4.2.Interleukins Antagonists
  • 5.4.3.Janus Kinase (JAK) Inhibitors
  • 5.4.4.Others

Chapter 6.Global Anti-Inflammatory Biologics Market, by Route of Administration

• 6.1.Market Snapshot
• 6.2.Global Anti-Inflammatory Biologics Market by Route of Administration, Performance - Potential Analysis
• 6.3.Global Anti-Inflammatory Biologics Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
• 6.4.Anti-Inflammatory Biologics Market, Sub Segment Analysis
  • 6.4.1.Oral
  • 6.4.2.Injection

Chapter 7.Global Anti-Inflammatory Biologics Market, by Application

• 7.1.Market Snapshot
• 7.2.Global Anti-Inflammatory Biologics Market by Application, Performance - Potential Analysis
• 7.3.Global Anti-Inflammatory Biologics Market Estimates & Forecasts by Application 2020-2030 (USD Billion)
• 7.4.Anti-Inflammatory Biologics Market, Sub Segment Analysis
  • 7.4.1.Rheumatoid Arthritis
  • 7.4.2.Psoriasis
  • 7.4.3.Others

Chapter 8.Anti-Inflammatory Biologics Market, by Distribution Channel

• 8.1.Market Snapshot
• 8.2.Global Anti-Inflammatory Biologics Market by Distribution Channel, Performance - Potential Analysis
• 8.3.Global Anti-Inflammatory Biologics Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
• 8.4.Anti-Inflammatory Biologics Market, Sub Segment Analysis
  • 8.4.1.Hospital Pharmacy
  • 8.4.2.Retail Pharmacy
  • 8.4.3.Online Pharmacy

Chapter 9.Global Anti-Inflammatory Biologics Market, Regional Analysis

• 9.1.Top Leading Countries
• 9.2.Top Emerging Countries
• 9.3.Anti-Inflammatory Biologics Market, Regional Market Snapshot
• 9.4.North America Anti-Inflammatory Biologics Market
  • 9.4.1.U.S. Anti-Inflammatory Biologics Market
    • 9.4.1.1.Drug Class breakdown estimates & forecasts, 2020-2030
    • 9.4.1.2.Route of Administration breakdown estimates & forecasts, 2020-2030
    • 9.4.1.3.Application breakdown estimates & forecasts, 2020-2030
    • 9.4.1.4.Distribution Channel breakdown estimates & forecasts, 2020-2030
  • 9.4.2.Canada Anti-Inflammatory Biologics Market
• 9.5.Europe Anti-Inflammatory Biologics Market Snapshot
  • 9.5.1.U.K. Anti-Inflammatory Biologics Market
  • 9.5.2.Germany Anti-Inflammatory Biologics Market
  • 9.5.3.France Anti-Inflammatory Biologics Market
  • 9.5.4.Spain Anti-Inflammatory Biologics Market
  • 9.5.5.Italy Anti-Inflammatory Biologics Market
  • 9.5.6.Rest of Europe Anti-Inflammatory Biologics Market
• 9.6.Asia-Pacific Anti-Inflammatory Biologics Market Snapshot
  • 9.6.1.China Anti-Inflammatory Biologics Market
  • 9.6.2.India Anti-Inflammatory Biologics Market
  • 9.6.3.Japan Anti-Inflammatory Biologics Market
  • 9.6.4.Australia Anti-Inflammatory Biologics Market
  • 9.6.5.South Korea Anti-Inflammatory Biologics Market
  • 9.6.6.Rest of Asia Pacific Anti-Inflammatory Biologics Market
• 9.7.Latin America Anti-Inflammatory Biologics Market Snapshot
  • 9.7.1.Brazil Anti-Inflammatory Biologics Market
  • 9.7.2.Mexico Anti-Inflammatory Biologics Market
• 9.8.Middle East & Africa Anti-Inflammatory Biologics Market
  • 9.8.1.Saudi Arabia Anti-Inflammatory Biologics Market
  • 9.8.2.South Africa Anti-Inflammatory Biologics Market
  • 9.8.3.Rest of Middle East & Africa Anti-Inflammatory Biologics Market

Chapter 10.Competitive Intelligence

• 10.1.Key Company SWOT Analysis
• 10.2.Top Market Strategies
• 10.3.Company Profiles
  • 10.3.1.AbbVie Inc. (U.S.)
    • 10.3.1.1.Key Information
    • 10.3.1.2.Overview
    • 10.3.1.3.Financial (Subject to Data Availability)
    • 10.3.1.4.Product Summary
    • 10.3.1.5.Recent Developments
  • 10.3.2.Merck & Co., Inc. (U.S.)
  • 10.3.3.Bristol-Myers Squibb Company (U.S.)
  • 10.3.4.Johnson & Johnson Services, Inc. (U.S.)
  • 10.3.5.Pfizer Inc. (U.S.)
  • 10.3.6.Novartis AG (Switzerland)
  • 10.3.7.UCB S.A. (Belgium)
  • 10.3.8.Eli Lilly and Company (U.S.)
  • 10.3.9.Amgen Inc. (U.S.)
  • 10.3.10.Biogen (U.S.)

Chapter 11.Research Process

• 11.1.Research Process
  • 11.1.1.Data Mining
  • 11.1.2.Analysis
  • 11.1.3.Market Estimation
  • 11.1.4.Validation
  • 11.1.5.Publishing
• 11.2.Research Attributes
• 11.3.Research Assumption